| |
 |
|
Class Information
Number: 514/2
Name: Drug, bio-affecting and body treating compositions > Designated organic active ingredient containing (doai) > Peptide containing (e.g., protein, peptones, fibrinogen, etc.) doai
Description: Subject matter which contains a protein or its reaction product, e.g., peptides, peptones, fibrinogen, etc., wherein the protein molecule is not degraded to the constituent amino-acids.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 514/14 |
12 to 15 peptide repeating units in known peptide chain |
1,115 |
| 514/13 |
16 to 24 peptide repeating units in known peptide chain |
1,152 |
| 514/19 |
2 peptide repeating units in known peptide chain |
1,319 |
| 514/12 |
25 or more peptide repeating units in known peptide chain structure |
5,587 |
| 514/18 |
3 or 4 peptide repeating units in known peptide chain |
1,594 |
| 514/17 |
5 or 6 peptide repeating units in known peptide chain |
1,070 |
| 514/16 |
7 or 8 peptide repeating units in known peptide chain |
1,047 |
| 514/15 |
9 to 11 peptide repeating units in known peptide chain |
1,374 |
| 514/9 |
Cyclopeptides |
698 |
| 514/8 |
Glycoprotein (carbohydrate containing) |
2,032 |
| 514/6 |
Heavy metal containing (e.g., hemoglobin, etc.) |
451 |
| 514/3 |
Insulin or derivative |
607 |
| 514/5 |
Iodine containing |
42 |
| 514/7 |
Phosphorus containing |
196 |
| 514/21 |
Produced by or extracted from animal tissue |
2,378 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 7338929 |
Cancer immunotherapy |
Mar. 4, 2008 |
| 7338766 |
Compositions and methods for treating malaria with cupredoxin and cytochrome |
Mar. 4, 2008 |
| 7335644 |
Anti-hypertensive molecules and process for preparation thereof |
Feb. 26, 2008 |
| 7335643 |
Compositions of active Wnt protein |
Feb. 26, 2008 |
| 7335642 |
Method for treating a viral infection related or a chemical toxin related hepatic injury with deltorphin D |
Feb. 26, 2008 |
| 7335640 |
Administration of hypocretin-1 for treatment of narcolepsy |
Feb. 26, 2008 |
| 7335637 |
Biglycan and related therapeutics and methods of use |
Feb. 26, 2008 |
| 7335636 |
SPRR1A and axonal regeneration |
Feb. 26, 2008 |
| 7335634 |
Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers |
Feb. 26, 2008 |
| 7335633 |
Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same |
Feb. 26, 2008 |
| 7335632 |
Beta-secretase inhibitors and methods of use thereof |
Feb. 26, 2008 |
| 7335490 |
Use of erythropoietin for the preventive or curative treatment of cardiac failure |
Feb. 26, 2008 |
| 7335362 |
Methods of treating pre-eclampsia or eclampsia |
Feb. 26, 2008 |
| 7335350 |
Chemokines mutants having improved oral bioavailability |
Feb. 26, 2008 |
| 7332475 |
Preventive or therapeutic composition for viral infectious disease |
Feb. 19, 2008 |
| 7332473 |
Peptides and medicinal compositions containing the same |
Feb. 19, 2008 |
| 7332470 |
Methods and compositions for treating ocular disease |
Feb. 19, 2008 |
| 7332469 |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
Feb. 19, 2008 |
| 7332164 |
Heterobifunctional polymeric bioconjugates |
Feb. 19, 2008 |
| 7332156 |
Methods of treating wounds using IL-23 |
Feb. 19, 2008 |
| 7329650 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases |
Feb. 12, 2008 |
| 7329645 |
TGF-.alpha. polypeptides, functional fragments and methods of use therefor |
Feb. 12, 2008 |
| 7329640 |
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
Feb. 12, 2008 |
| 7329639 |
Peptide useful in immunomodulation |
Feb. 12, 2008 |
| 7329638 |
Drug delivery compositions |
Feb. 12, 2008 |
| 7329541 |
Zinc finger binding domains for GNN |
Feb. 12, 2008 |
| 7329410 |
Compositions and method for WT1 specific immunotherapy |
Feb. 12, 2008 |
| 7329402 |
Methods of imaging and treatment |
Feb. 12, 2008 |
| 7326683 |
Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
Feb. 5, 2008 |
| 7326682 |
Conotoxin peptides |
Feb. 5, 2008 |
| 7326679 |
Anticancer peptide compositions |
Feb. 5, 2008 |
| 7326678 |
GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof |
Feb. 5, 2008 |
| 7326536 |
Agents for treatment of HCV and methods of use |
Feb. 5, 2008 |
| 7326425 |
Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
Feb. 5, 2008 |
| 7326412 |
Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation |
Feb. 5, 2008 |
| 7326411 |
Use of amino-terminally truncated RANTES to inhibit HIV viral replication |
Feb. 5, 2008 |
| 7324846 |
Method of enchancing electrontransport polypeptide flux by amino acid substitution with histidine |
Jan. 29, 2008 |
| 7323445 |
Methods and compositions for healing and repair of articular cartilage |
Jan. 29, 2008 |
| 7323441 |
Use of lupin conglutin for the treatment of type II diabetes |
Jan. 29, 2008 |
| 7323440 |
De-immunized MOG (poly)peptide constructs |
Jan. 29, 2008 |
| 7323439 |
Methods and compositions for modulating angiogenesis |
Jan. 29, 2008 |
| 7323181 |
Compositions and methods for WT1 specific immunotherapy |
Jan. 29, 2008 |
| 7323179 |
Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
Jan. 29, 2008 |
| 7323173 |
Methods for treating breast cancer using a mammary cell growth inhibitor |
Jan. 29, 2008 |
| 7323171 |
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
Jan. 29, 2008 |
| 7323169 |
Sustained release formulations |
Jan. 29, 2008 |
| 7320958 |
Coleopteran-toxic polypeptide compositions |
Jan. 22, 2008 |
| 7320788 |
Enzyme treatment of foodstuffs for Celiac Sprue |
Jan. 22, 2008 |
| 7320783 |
Methods and compositions for the enhancement of wound healing |
Jan. 22, 2008 |
| 7319092 |
Methods of suppressing microglial activation |
Jan. 15, 2008 |
|
|
|
